

**LINCOLN PHARMACEUTICALS LIMITED**

REGD.OFFICE: "LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.

(Rs. in Lacs)

**UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31.12.2012**

PART - I PARTICULARS	CONSOLIDATED						STANDALONE					
	QUARTER ENDED		NINE MONTH ENDED			YEAR ENDED	QUARTER ENDED		NINE MONTH ENDED			YEAR ENDED
	31.12.2012 (Un-Audited)	30.09.2012 (Un-Audited)	30.12.2011 (Un-Audited)	31.12.2012 (Un-Audited)	31.12.2011 (Un-Audited)	31.03.2012 (Audited)	31.12.2012 (Un-Audited)	30.09.2012 (Un-Audited)	30.12.2011 (Un-Audited)	31.12.2012 (Un-Audited)	31.12.2011 (Un-Audited)	31.03.2012 (Audited)
1 Income from operations												
(a) Net Sales/Income from operation (Net of excise duty)	5109.95	5543.94	5452.90	13608.38	13938.58	17545.65	4891.38	5384.76	5352.15	13230.41	13481.33	17416.13
(b) Other operating income	74.89	-15.31	18.14	130.27	116.95	354.12	76.88	-16.16	18.14	128.82	108.98	338.45
<b>Total income from operations (net)</b>	<b>5184.84</b>	<b>5528.63</b>	<b>5472.04</b>	<b>13738.65</b>	<b>14057.53</b>	<b>17899.77</b>	<b>4968.26</b>	<b>5368.60</b>	<b>5371.29</b>	<b>13359.23</b>	<b>13590.31</b>	<b>17755.58</b>
2 Expenses												
(a) Cost of materials consumed	761.58	1459.06	723.01	2948.32	2815.39	3626.69	609.41	1425.11	723.01	2762.81	2615.39	3566.06
(b) Purchases of stock-in-trade	2778.56	2246.44	2601.30	5957.77	5551.06	7023.49	2778.56	2172.74	2494.56	5890.07	5228.72	7156.26
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-122.27	-36.90	263.32	-254.33	554.08	485.49	-83.59	-32.34	263.32	-211.09	449.44	380.85
(d) Employee benefits expense	520.70	389.47	413.00	1341.29	1171.89	1622.11	468.61	353.26	413.00	1222.79	1171.89	1531.25
(e) Depreciation and amortisation expense	61.85	72.03	44.83	185.42	127.29	193.28	53.05	52.36	44.83	155.64	127.29	188.65
(f) Other expenses	930.34	841.51	1178.54	2518.80	2802.99	3449.88	852.19	812.26	1184.85	2409.52	2884.65	3454.18
<b>Total expenses</b>	<b>4931.16</b>	<b>4965.61</b>	<b>5224.00</b>	<b>12897.27</b>	<b>12922.70</b>	<b>16400.94</b>	<b>4678.23</b>	<b>4783.39</b>	<b>5123.57</b>	<b>12229.74</b>	<b>12477.38</b>	<b>16277.25</b>
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	253.68	563.02	248.04	1041.38	1134.83	1498.83	290.03	585.21	247.72	1129.49	1112.93	1478.33
4 Other income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	253.68	563.02	248.04	1041.38	1134.83	1498.83	290.03	585.21	247.72	1129.49	1112.93	1478.33
6 Finance costs	135.98	115.06	181.55	355.10	491.01	760.00	110.31	113.12	181.54	327.60	489.75	755.68
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	117.70	447.96	66.50	686.28	643.82	738.83	179.72	472.09	66.18	801.89	623.18	722.65
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	117.70	447.96	66.50	686.28	643.82	738.83	179.72	472.09	66.18	801.89	623.18	722.65
10 Tax expense	-3.58	159.03	14.55	195.33	208.45	226.02	-17.69	118.09	21.47	138.20	208.45	225.99
11 Net Profit / (Loss) from ordinary activities after tax (9 - 10)	121.28	288.93	51.94	490.95	435.37	512.81	197.41	354.00	44.71	663.69	414.73	496.66
12 Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11 + 12)	121.28	288.93	51.94	490.95	435.37	512.81	197.41	354.00	44.71	663.69	414.73	496.66
14 Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest*	-28.18	-38.19	0.00	-66.37	0.00	0.93	0.00	0.00	0.00	0.00	0.00	0.00
16 Net Profit / (Loss) after taxes, minority interest and shares of profit/(loss) of associates (13 - 14 + 15)	149.46	327.12	51.94	557.32	435.37	511.88	197.41	354.00	44.71	663.69	414.73	496.66
17 Paid-up equity share capital of face value Rs. 10/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18 Reserve excluding Revaluation Reserves as per balance sheet of previous a/c. year	-	-	-	-	-	6447.50	-	-	-	-	-	6386.62
19 (a) Basic and diluted EPS before Extraordinary items (i.v. 10/- each) and Prior period Adjustment (Not Annualised)	0.92	2.00	0.32	3.42	2.67	3.14	1.21	2.17	0.27	4.07	2.54	3.04
19 (b) Basic and diluted EPS after Extraordinary items (i.v. 10/- each) and Prior period Adjustment (Not Annualised)	0.92	2.00	0.32	3.42	2.67	3.14	1.21	2.17	0.27	4.07	2.54	3.04
<b>PART - II</b>												
<b>A PARTICULARS OF SHAREHOLDING</b>												
1 Public Shareholding												
-Number of shares	11737496	11591774	11589374	11737496	11589374	11589374	11737496	11591774	11589374	11737496	11589374	11589374
-Percentage of Shareholding	71.98	71.07	71.05	71.96	71.05	71.05	71.98	71.07	71.05	71.96	71.05	71.05
2 Promoters and Promoter group Shareholding:												
a) Pledged/Encumbered												
-Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
-Percentage of Shareholding (as a % of the total share capital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered												
-Number of shares	4573304	4719026	4721426	4573304	4721426	4721426	4573304	4719026	4721426	4573304	4721426	4721426
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
-Percentage of Shareholding (as a % of the total share capital of the Company)	28.04	28.93	28.95	28.04	28.95	28.95	28.04	28.93	28.95	28.04	28.95	28.95
<b>Particulars</b>	<b>Quarter ended on 31.12.2012</b>											
<b>B INVESTOR COMPLAINTS</b>												
Pending at the beginning of the quarter	NIL											
Received during the quarter	1											
Disposed of during the quarter	1											
Remaining unresolved at the end of the quarter	NIL											

**NOTES:-**

- The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 12.02.2013
- Previous year figures are regrouped/reclassified to conform to the current year's presentation.
- Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- Statutory Auditors has carried out limited review for the quarterly result for quarter ended 31.12.2012.
- Consolidated results includes results of its two subsidiary Company

Place : Ahmedabad.  
Date : 12.02.2013

for LINCOLN PHARMACEUTICALS LIMITED

*(Signature)*  
(Hasmukhbhai I. Patel)  
Whole-time Director

